Table 2.
Patient characteristics in surfactant and nonsurfactant groups
| Surfactant | Controls | Overall | Comments | |
|---|---|---|---|---|
| Randomized | 22 | 16 | 38 | − |
| Treated | 20 | 15 | 35 | −a |
| Age (range; years) | 3.5 (0–13) | 4.5 (0–12) | 3.9 (0–13) | n.s. |
| Female | 7 (35%) | 7 (46.7%) | 14 (40%) | − |
| Body weight (kg) | 15.7±10.4 | 22.4±20.7 | 18.6±15.8 | n.s. |
| Time since FIO2 >0.5 (h) | 35.2±25.5 | 49.8±44.5 | n.s. | |
| Time since PIP >30 cmH2O (h) | 24.9±21.8 | 34.1±32.9 | n.s. | |
| Causative diagnosis pneumonia | 15 (68.2%) | 11 (68.7%) | n.s. | |
| Causative diagnosis sepsis | 7 (31.8%) | 5 (31.3%) | n.s. | |
| Under immunosuppression | 9 | 7 | n.s. | |
| Rescue ECMO | 0 | 2 | −b | |
| Rescue NO | 4 | 4 | −b | |
| Rescue HFOV | 2 | 3 | −b | |
| Rescue surfactant | 0 | 4 | −b | |
| Rescue vasodilators | 1 | 1 | −b | |
| Nonsurvivors/mortality | 8 (44%) | 9 (60%) | p=0.29 | |
| Death and/or rescue | 11 (56%) | 12 (80%) | p=0.13 | |
| Ventilator-free (alive and without ventilator) | n.s. | |||
| 0 days | 12 (63.2%) | 9 (64.3%) | ||
| 10–20 days | 3 (15.8%) | 3 (21.4%) | ||
| >20 days | 4 (21.1%) | 2 (14.3%) | ||
| PRISM III at randomization, median | 11.5 | 11 | n.s. | |
| Lung injury score (Murray) at randomization | 3.0 | 3.3 | n.s. | |
| PaO2/FIO2 at baseline | 71.3±13.7 | 64.3±16.2 | n.s. | |
| 2nd surfactant dose | 11 | − |
aThree patients improved within the 2 h between reaching a PaO2/FIO2 <100 and final randomization
bRescue therapy after the study surfactant medication was given